MedTrace Logo

Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™

NCT02098200 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-03-14

No results posted yet for this study

Summary

The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation.

It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and relieve symptoms in patients with tricuspid valve regurgitation.

Conditions

  • Tricuspid Regurgitation

Interventions

DEVICE

TriCinch System

Percutaneous treatment of Tricuspid Regurgitation

Sponsors & Collaborators

  • 4Tech Cardio Ltd.

    lead INDUSTRY

Principal Investigators

  • Antonio Colombo, MD · San Raffaele Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-11-30
Completion
2017-10-31

Countries

  • France
  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02098200 on ClinicalTrials.gov